Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF®
Retrieved on:
Tuesday, March 31, 2020
The financing will fund the AEROSURF phase 2b bridge study which, if successful, is intended to transition the product into a phase 3 ready clinical product development.
Key Points:
- The financing will fund the AEROSURF phase 2b bridge study which, if successful, is intended to transition the product into a phase 3 ready clinical product development.
- The Term Sheet provides, among other things, that in connection with the continued development of AEROSURF, Lee's will make non-refundable payments to the Company during the period from April 1, 2020 through September 1, 2020.
- Windtree also has multiple pre-clinical programs, including potential heart failure therapies delivered orally that are based on SERCA2a mechanism of action.
- Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release.